MARKET

GALT

GALT

Galectin Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.230
+0.020
+0.48%
After Hours: 4.230 0 0.00% 17:59 05/14 EDT
OPEN
4.205
PREV CLOSE
4.210
HIGH
4.500
LOW
4.030
VOLUME
863.05K
TURNOVER
--
52 WEEK HIGH
5.70
52 WEEK LOW
1.820
MARKET CAP
241.77M
P/E (TTM)
-10.2223
1D
5D
1M
3M
1Y
5Y
Global Myocardial Fibrosis Market Size, Share, Value, and Competitive Landscape 2020
May 04, 2021 (Heraldkeepers) -- Global Myocardial Fibrosis Market Overview:Global Myocardial Fibrosis Market Report 2020 comes with the extensive industry...
Heraldkeepers · 05/05 00:17
Insider Trends: Galectin Therapeutics Insider Sale Interrupting 90-Day Buy Trend
MT Newswires · 05/04 17:06
52 Biggest Movers From Yesterday
Gainers Regional Health Properties, Inc. (NYSE: RHE) shares climbed 102.5% to close at $14.62 on Monday after jumping 38% on Friday.
Benzinga · 05/04 09:00
32 Stocks Moving In Monday's Mid-Day Session
Gainers Regional Health Properties, Inc. (NYSE: RHE) shares jumped 99.7% to $14.42 after jumping 38% on Friday.
Benzinga · 05/03 16:00
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)
Benzinga · 04/30 11:31
VER, CARA, GALT and OCUL among midday movers
Gainers: Willamette Valley Vineyards (WVVI) +55%.Ocular Therapeutix (OCUL) +23%.Galera Therapeutics (GRTX) +23%.JAKKS Pacific (JAKK) +21%.ShiftPixy (PIXY) +19%.1-800-FLOWERS.COM (FLWS) +18%.MEDIROM Healthcare Technologies (MRM) +16%.VEREIT (VER) +16%.Commu...
Seekingalpha · 04/29 16:40
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28)
Benzinga · 04/29 12:15
Stocks That Hit 52-Week Highs On Wednesday
    During the morning session on Wednesday, 217 stocks hit new 52-week highs.
Benzinga · 04/28 14:13
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GALT. Analyze the recent business situations of Galectin Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GALT stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 107
Institutional Holdings: 10.55M
% Owned: 18.46%
Shares Outstanding: 57.16M
TypeInstitutionsShares
Increased
7
174.25K
New
1
1.00K
Decreased
12
857.01K
Sold Out
3
286.63K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Non-Executive Chairman/Independent Director
Richard Uihlein
President/Chief Executive Officer/Director
Joel Lewis
Chief Financial Officer/Secretary
Jack Callicutt
Executive Vice President
Eliezer Zomer
Executive Director
Adam Allgood
Other
Pol Boudes
Other
J. Rex Horton
Director
James Czirr
Director
Harold Shlevin
Independent Director
Gilbert Amelio
Independent Director
Kary Eldred
Independent Director
Kevin Freeman
Independent Director
Gilbert Omenn
Independent Director
Marc Rubin
Independent Director
Elissa Schwartz
Independent Director
Richard Zordani
No Data
About GALT
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Webull offers kinds of Galectin Therapeutics Inc stock information, including NASDAQ:GALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GALT stock methods without spending real money on the virtual paper trading platform.